| StreetInsider.com - Insiders' Edge |  | | Goldman Sachs (GS) Has Another Hurdle To Clear |  | Many speculate that Goldman Sachs (NYSE: GS) will announce its first quarterly loss (due to writedowns) this quarter, when it announces Q4 earnings on December 15th. Last year, Goldman generated $2.8 billion in Q3 net income, and this year in Q3, Goldman Sachs produced $845 million. Goldman's income has fallen as trading and investment banking business has declined.
Goldman Sachs has yet to lose money on yearly basis, but Goldman Sachs has yet additional hurdle in its way to continue its profitability streak. Goldman Sachs now has to annually pay out $1 billion in dividends to the Treasury and Warren Buffett.
Berkshire's $5 billion investment in Goldman Sachs pays a 10% dividend, an annual expense for Goldman of $500 million. Additionally, the treasury's $10 billion pays a 5% dividend, or another $500 million. That's a total of $1 billion in new expenses that Goldman Sachs now has to incur.
The challenge for Goldman Sachs' CEO Lloyd Blankfein is to find new revenue sources as the economy sputters. If Blankfein is able to find those new sources then Goldman should be able to continue its yearly profitability streak.
More Insiders' Blog: http://www.streetinsider.com/Insiders+Blog FREE RSS Feed: http://www.streetinsider.com/freefeed.php?cid=6 | | | 
| Insider Trade of the Day - Unisys (UIS) Unisys Corp. (NYSE: UIS) is seeing more insider buying today. In addition to the new CEO Ed Coleman buying 141,000,which we noted earlier, VP Anthony Doye bought 100,000 on 11/10 and Director Charles McQuade bought 100,000 shares.
More Insider Trades ($): http://www.streetinsider.com/Insider+Trades | | 
| | Upgrade To Watch - Gilead (GILD) Needham & Co initiates coverage on Gilead Sciences (Nasdaq: GILD) with a Buy. Price target $51.
Needham analyst says, "We expect Atripla and Truvada, to further penetrate the U.S. and European markets for the next several years due to the simplicity they bring to HIV treatment and new U.S. and international guidelines favoring Gilead products. We believe the company’s strong competitive position in the HIV space, as well as its potential for maintaining this ... MORE
More Upgades: http://www.streetinsider.com/Upgrades FREE Upgrade RSS: http://www.streetinsider.com/freefeed.php?cid=9 |  | | 
| | Keep up with all the breaking, market-moving news on Wall Street with StreetInsider.com Premium. $29 per month, $80 for 90 days, $150 for 180 days, or $250 per year. UPGRADE TO STREETINSIDER.COM PREMIUM | | | | | | | |
To unsubscribe/change profile: click here
To subscribe: click here
Our address: 725 S. Adams Suite 287
Birmingham, Michigan 48009
Email list management powered by http://MailerMailer.com
